An antibody for myelofibrosis – “that’s a true discovery”
A new monoclonal antibody, discovered by accident by Adelaide researchers, could become the world’s first effective treatment for primary myelofibrosis (MF).
- Myeloproliferative neoplasms
A new monoclonal antibody, discovered by accident by Adelaide researchers, could become the world’s first effective treatment for primary myelofibrosis (MF).
Professor Wendy Erber and her research team in Western Australia are developing a monitoring tool they hope will identify MPN patients who will go on to develop leukaemia.
To kick off Season Two, we chat to Tim Keen who was 34 years old when he was diagnosed with a rare subtype of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APML). Tim shares his story through diagnosis, relapse, and treatment, where he underwent two autologous transplants and arsnic treatment.
The Leukaemia Foundation has welcomed news that for the first time, a targeted treatment option will now be available for Waldenström macroglobulinemia (WM) patients through the Pharmaceutical Benefits Scheme (PBS).